US pharmaceutical companies may be counting their lucky stars now that healthcare reform is a dead issue for the time being. But they shouldn’t. They are still very vulnerable to increasing political pressure from the Trump Administration. The good news is there are actions these companies can take in the face of this pressure, and these actions are equally applicable by companies in other industries.
The pharmaceutical industry is an attractive target for the new Administration to attack. The Administration may not be able to get all its legislation passed, but it still has substantial ability to affect public opinion and utilize substantial power over many industries, healthcare being primary at this time. Pharmaceutical companies are a case in point. Here’s why: